Sequential administration of anti-complement component C5 eculizumab and type-2 anti-CD20 obinutuzumab for the treatment of early antibody-mediated rejection after kidney transplantation: A proof of concept

Autor: Favi, Evaldo a, b, ⁎, Cresseri, Donata c, Perego, Marta a, Ikehata, Masami d, Iesari, Samuele a, Campise, Maria Rosaria c, Morello, William e, Testa, Sara e, Sioli, Viviana f, Mattinzoli, Deborah d, Longhi, Elena f, Del Gobbo, Alessandro g, Castellano, Giuseppe b, c, Ferraresso, Mariano a, b
Zdroj: In Clinical Immunology July 2024 264
Databáze: ScienceDirect
Externí odkaz: